Atsena Therapeutics, a clinical-stage gene therapy company, announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.

Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness' RD Fund, along with existing investors Osage University Partners, University of Florida, and Manning Family Foundation, also participated in the round.

Atsena Therapeutics is a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness. The company's ongoing Phase I/II clinical trial is evaluating a potential therapy for one of the most common causes of blindness in children. Its additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease, and its unique approach is guided by the specific needs of each patient condition to optimize treatment.